198 related articles for article (PubMed ID: 23469567)
21. Thalidomide plus monthly high-dose dexamethasone in chemorefractory myeloma. Results of a phase II clinical study.
Bernardeschi P; Giustarini G; Montenora I; Turrisi G; Dentico P; Rossi S; Turano E; Fiorentini G
In Vivo; 2006; 20(6A):719-20. PubMed ID: 17203753
[TBL] [Abstract][Full Text] [Related]
22. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
23. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
Bensinger WI; Jagannath S; Vescio R; Camacho E; Wolf J; Irwin D; Capo G; McKinley M; Potts P; Vesole DH; Mazumder A; Crowley J; Becker P; Hilger J; Durie BG
Br J Haematol; 2010 Feb; 148(4):562-8. PubMed ID: 19919652
[TBL] [Abstract][Full Text] [Related]
24. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
Badros A; Goloubeva O; Fenton R; Rapoport AP; Akpek G; Harris C; Ruehle K; Westphal S; Meisenberg B
Clin Lymphoma Myeloma; 2006 Nov; 7(3):210-6. PubMed ID: 17229337
[TBL] [Abstract][Full Text] [Related]
25. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus doxorubicin and dexamethasone as induction therapy in previously untreated multiple myeloma patients.
Buda G; Orciuolo E; Carulli G; Galimberti S; Ghio F; Cervetti G; Pelosini M; Petrini M
Acta Haematol; 2013; 129(1):35-9. PubMed ID: 23107867
[TBL] [Abstract][Full Text] [Related]
26. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.
Steurer M; Spizzo G; Mitterer M; Gastl G
Onkologie; 2004 Apr; 27(2):150-4. PubMed ID: 15138347
[TBL] [Abstract][Full Text] [Related]
27. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
Rajkumar SV; Blood E; Vesole D; Fonseca R; Greipp PR;
J Clin Oncol; 2006 Jan; 24(3):431-6. PubMed ID: 16365178
[TBL] [Abstract][Full Text] [Related]
28. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.
Schütt P; Ebeling P; Buttkereit U; Brandhorst D; Opalka B; Hoiczyk M; Flasshove M; Hense J; Bojko P; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2005 Jan; 74(1):40-6. PubMed ID: 15613105
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
Ai Zheng; 2007 Dec; 26(12):1369-72. PubMed ID: 18076804
[TBL] [Abstract][Full Text] [Related]
30. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma.
Kumar S; Witzig TE; Dispenzieri A; Lacy MQ; Wellik LE; Fonseca R; Lust JA; Gertz MA; Kyle RA; Greipp PR; Rajkumar SV
Leukemia; 2004 Mar; 18(3):624-7. PubMed ID: 14749707
[TBL] [Abstract][Full Text] [Related]
31. [The efficacy of thalidomide for multiple myeloma: a clinical analysis of 102 Chinese patients].
Qi PJ; Wang YF; Xu Y; Li YN; Zou DH; Zhao YZ; Xiao ZJ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):226-9. PubMed ID: 18843974
[TBL] [Abstract][Full Text] [Related]
32. [Retrospective analysis of thalidomide therapy in patients with relapsed/refractory multiple myeloma].
Ikebe T; Ogata M; Miyazaki M; Miyazaki Y; Ohtsuka E; Saburi Y; Goto K; Ikewaki J; Kohno K; Uno N; Imamura T; Akagi T; Kadota J
Rinsho Ketsueki; 2010 Feb; 51(2):114-21. PubMed ID: 20379102
[TBL] [Abstract][Full Text] [Related]
33. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR
Bone Marrow Transplant; 2002 Apr; 29(7):577-80. PubMed ID: 11979306
[TBL] [Abstract][Full Text] [Related]
34. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.
Ladetto M; Pagliano G; Ferrero S; Cavallo F; Drandi D; Santo L; Crippa C; De Rosa L; Pregno P; Grasso M; Liberati AM; Caravita T; Pisani F; Guglielmelli T; Callea V; Musto P; Cangialosi C; Passera R; Boccadoro M; Palumbo A
J Clin Oncol; 2010 Apr; 28(12):2077-84. PubMed ID: 20308672
[TBL] [Abstract][Full Text] [Related]
35. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
Jakubowiak AJ; Richardson PG; Zimmerman T; Alsina M; Kaufman JL; Kandarpa M; Kraftson S; Ross CW; Harvey C; Hideshima T; Sportelli P; Poradosu E; Gardner L; Giusti K; Anderson KC
Br J Haematol; 2012 Aug; 158(4):472-80. PubMed ID: 22640031
[TBL] [Abstract][Full Text] [Related]
36. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma.
Kyriakou C; Thomson K; D'Sa S; Flory A; Hanslip J; Goldstone AH; Yong KL
Br J Haematol; 2005 Jun; 129(6):763-70. PubMed ID: 15953002
[TBL] [Abstract][Full Text] [Related]
37. A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma.
Kodama T; Abe M; Iida S; Ozaki S; Sakai A; Sawamura M; Shimazaki C; Miyata A; Wakayama T; Murakami H
Clin Lymphoma Myeloma; 2009 Apr; 9(2):154-9. PubMed ID: 19406727
[TBL] [Abstract][Full Text] [Related]
38. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma.
Abdelkefi A; Torjman L; Ben Romdhane N; Ladeb S; El Omri H; Ben Othman T; Elloumi M; Bellaj H; Lakhal A; Jeddi R; Aissaouï L; Saad A; Hsaïri M; Boukef K; Dellagi K; Ben Abdeladhim A
Bone Marrow Transplant; 2005 Aug; 36(3):193-8. PubMed ID: 15968290
[TBL] [Abstract][Full Text] [Related]
39. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E
Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386
[TBL] [Abstract][Full Text] [Related]
40. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio.
Terpos E; Mihou D; Szydlo R; Tsimirika K; Karkantaris C; Politou M; Voskaridou E; Rahemtulla A; Dimopoulos MA; Zervas K
Leukemia; 2005 Nov; 19(11):1969-76. PubMed ID: 16079895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
